肝疾患診断のアジア太平洋市場2020-2026:エンドユーザー別(病院、研究所、その他)、診断技術別、地域別

【英語タイトル】Asia Pacific Liver Disease Diagnostics Market By End User (Hospitals, Laboratories and Other End Users), By Diagnosis Technique (Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques), By Country, Industry Analysis and Forecast, 2020 - 2026

KBV Researchが出版した調査資料(KBV20OCT180)・商品コード:KBV20OCT180
・発行会社(調査会社):KBV Research
・発行日:2020年6月30日
・ページ数:83
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:中国、日本、インド、韓国、シンガポール、マレーシア
・産業分野:健康管理
◆販売価格オプション(消費税別)
Single User(1名様利用)USD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Global License(法人利用)USD2,520 ⇒換算¥264,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本市場調査レポートでは、肝疾患診断のアジア太平洋市場について、市場範囲・調査手法、市場概要、エンドユーザー別(病院、研究所、その他)分析、診断技術別分析、地域別分析、企業概要などを総合的、多面的に調査・分析しました。
・市場範囲・調査手法
・市場概要
・肝疾患診断のアジア太平洋市場規模:エンドユーザー別(病院、研究所、その他)
・肝疾患診断のアジア太平洋市場規模:診断技術別
・肝疾患診断のアジア太平洋市場規模:地域別
・企業概要
【レポートの概要】

The Asia Pacific Liver Disease Diagnostics Market would witness market growth of 7.9% CAGR during the forecast period (2020-2026).

The market in the Asia Pacific is projected to rise significantly during the forecast period. The growing geriatric population and awareness of regular check-ups are contributing to the growth of the liver disease diagnostics market in this country. In addition, it is projected that the regulatory acceptance of emerging technology that can be incorporated with imaging systems would fuel regional growth. For example, in August 2018, LiverMultiScan obtained approval from Therapeutic Goods Administration (TGA) to treat patients with highly prevalent diseases in Australia such as NAFLD and NASH.

An unhealthy diet, high-stress levels, and unorganized lifestyle patterns are the main drivers of the liver disease treatment market. Overweight and obesity rates in developing countries have increased dramatically, raising the chances of liver disease. In addition, increased alcohol consumption has fueled an increase in fatal liver disease. These factors also increased incidences of liver disease, which will fuel the growth of the liver disease treatment market in the future. Different strategies for the development of emerging technologies to advance patient care are being applied by key players.

Aging is a condition in which a person is gradually losing the ability to maintain homeostasis due to structural alteration or dysfunction. Aging is a major risk factor for the majority of chronic diseases. Aging has been shown not only to increase the vulnerability of acute liver injury but also to increase the susceptibility of fibrotic reactions. Aging is associated with the severity and poor prognosis of various diseases of the liver, including non-alcoholic fatty liver disease, alcoholic liver disease, hepatitis C, and liver transplantation.

Structural dysfunction or modification due to aging primarily contributes to diseases of the liver. According to the National Institute of Aging, the geriatric population is expected to grow by 86% by 2050. Increased rates of the geriatric population have resulted in an increase in the incidence of liver disease, which has further increased the demand for the liver disease treatment market.

Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited

Scope of the Study
Market Segmentation:

By End User
• Hospitals, Laboratories and Other End Users

By Diagnosis Technique
• Imaging
• Biopsy
• Endoscopy
• Laboratory tests and
• Other Diagnosis Techniques

By Country
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Companies Profiled
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Boston Scientific Corporation
• Siemens AG (Siemens Healthineers)
• Bayer AG
• Merck & Co., Inc.
• Sanofi S.A.
• Novartis AG
• Pfizer, Inc.
• Randox laboratories limited

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Liver Disease Diagnostics Market, by End User
1.4.2 Asia Pacific Liver Disease Diagnostics Market, by Diagnosis Technique
1.4.3 Asia Pacific Liver Disease Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Liver Disease Diagnostics Market by End User
3.1 Asia Pacific Hospitals Market by Country
3.2 Asia Pacific Laboratories Market by Country
3.3 Asia Pacific Other End Users Market by Country
Chapter 4. Asia Pacific Liver Disease Diagnostics Market by Diagnosis Technique
4.1 Asia Pacific Imaging Market by Country
4.2 Asia Pacific Biopsy Market by Country
4.3 Asia Pacific Endoscopy Market by Country
4.4 Asia Pacific Laboratory tests Market by Country
4.5 Asia Pacific Other Diagnosis Techniques Market by Country
Chapter 5. Asia Pacific Liver Disease Diagnostics Market by Country
5.1 China Liver Disease Diagnostics Market
5.1.1 China Liver Disease Diagnostics Market by End User
5.1.2 China Liver Disease Diagnostics Market by Diagnosis Technique
5.2 Japan Liver Disease Diagnostics Market
5.2.1 Japan Liver Disease Diagnostics Market by End User
5.2.2 Japan Liver Disease Diagnostics Market by Diagnosis Technique
5.3 India Liver Disease Diagnostics Market
5.3.1 India Liver Disease Diagnostics Market by End User
5.3.2 India Liver Disease Diagnostics Market by Diagnosis Technique
5.4 South Korea Liver Disease Diagnostics Market
5.4.1 South Korea Liver Disease Diagnostics Market by End User
5.4.2 South Korea Liver Disease Diagnostics Market by Diagnosis Technique
5.5 Singapore Liver Disease Diagnostics Market
5.5.1 Singapore Liver Disease Diagnostics Market by End User
5.5.2 Singapore Liver Disease Diagnostics Market by Diagnosis Technique
5.6 Malaysia Liver Disease Diagnostics Market
5.6.1.1.1 Malaysia Liver Disease Diagnostics Market by End User
5.6.2 Malaysia Liver Disease Diagnostics Market by Diagnosis Technique
5.7 Rest of Asia Pacific Liver Disease Diagnostics Market
5.7.1 Rest of Asia Pacific Liver Disease Diagnostics Market by End User
5.7.2 Rest of Asia Pacific Liver Disease Diagnostics Market by Diagnosis Technique
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.1.5.3 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Approvals:
6.3 Boston Scientific Corporation
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Acquisition and Mergers:
6.4 Siemens AG (Siemens Healthineers)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Acquisition and Mergers:
6.4.5.3 Product Launches and Product Expansions:
6.5 Bayer AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Merck & Co., Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Randox Laboratories Limited
6.10.1 Company Overview



★調査レポート[肝疾患診断のアジア太平洋市場2020-2026:エンドユーザー別(病院、研究所、その他)、診断技術別、地域別] (コード:KBV20OCT180)販売に関する免責事項を必ずご確認ください。
★調査レポート[肝疾患診断のアジア太平洋市場2020-2026:エンドユーザー別(病院、研究所、その他)、診断技術別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆